Amarantus BioScience Holdings Inc. announced that it has established an Alzheimer's disease Diagnostics Scientific Advisory Board (SAB) and appointed three specialists in Alzheimer's disease (AD) and neurological disorders, Paula T. Trzepacz, M.D., Jeffrey L. Cummings, M.D., Sc.D., and Robert A. Stern, Ph.D., as its first members. The company expects to expand the SAB during the first half of 2015. Most recently Dr. Trzepacz was a Senior Medical Fellow at Eli Lilly and Company (Lilly) focused on amyloid assessment in evaluation of cognitive impairment and the scientific exploration of the relationship of a variety of biomarkers across the continuum of Alzheimer's disease.

Her role at Lilly neuroscience also included registration experience, Phase 2 through Phase 4 clinical programs, and leading the Phase 2 program on mibampator for agitation and aggression in AD. Dr. Cummings is a leading expert in neuropsychiatry of neurologic disorders, biomarkers for neurodegenerative diseases, and an experienced clinical trialist with expertise in trial design and analysis, global trial implementation, and trial outcome measures. He is Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio.

Dr. Stern's major focus of research expertise is on the long-term effects of repetitive brain trauma in athletes, including the neurodegenerative disease, Chronic Traumatic Encephalopathy (CTE). Dr. Stern was formerly on the faculty at University of North Carolina, where he was the Associate Director of the NIMH-funded Mental Health Clinical Research Center, and Director of the Neurobehavioral Assessment Core.